NASDAQ, ARRY - Array Technologies Inc

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery,  development and commercialization of targeted small molecule drugs to treat  cancer and inflammatory diseases. Our proprietary drug development pipeline  includes clinical candidates that are designed to regulate therapeutically  important target proteins and are aimed at large market opportunities. We  currently have 10 programs in our development pipeline, eight of which are  wholly owned by us.  Our eight most advanced development programs that we wholly own and control  consist of ARRY-543, an ErbB-2/EFGR dual inhibitor for cancer; ARRY-162, a MEK  inhibitor for inflammation; ARRY-797, a p38 inhibitor for inflammation and for  cancer; ARRY-520, a KSP inhibitor for cancer; ARRY-380, an ErbB-2 inhibitor for  cancer; and ARRY-614, a p38/Tie 2 dual inhibitor for inflammation and for  cancer.  ...

Sector:	Consumer Durables
Industry:	Major Pharmaceuticals
P/E Ratio:	8.8523
PEG Ratio:	N/A
EPS:	N/A
DivYield:	N/A
PtB:	N/A
PtS:	41.12
EBITDA:	N/A
Shares:	152.55M
Market Cap:	839.01M
52wk range:	3.76 - 9.34

216.73.216.229
United States